H4octapa: An Acyclic Chelator for 111In Radiopharmaceuticals
- 11 May 2012
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 134 (20) , 8670-8683
- https://doi.org/10.1021/ja3024725
Abstract
This preliminary investigation of the octadentate acyclic chelator H4octapa (N4O4) with 111In/115In3+ has demonstrated it to be an improvement on the shortcomings of the current industry “gold standards” DOTA (N4O4) and DTPA (N3O5). The ability of H4octapa to radiolabel quantitatively 111InCl3 at ambient temperature in 10 min with specific activities as high as 2.3 mCi/nmol (97.5% radiochemical yield) is presented. In vitro mouse serum stability assays have demonstrated the 111In complex of H4octapa to have improved stability when compared to DOTA and DTPA over 24 h. Mouse biodistribution studies have shown that the radiometal complex [111In(octapa)]− has exceptionally high in vivo stability over 24 h with improved clearance and stability compared to [111In(DOTA)]−, demonstrated by lower uptake in the kidneys, liver, and spleen at 24 h. 1H/13C NMR studies of the [In(octapa)]− complex revealed a 7-coordinate solution structure, which forms a single isomer and exhibits no observable fluxional behavior at ambient temperature, an improvement to the multiple isomers formed by [In(DTPA)]2– and [In(DOTA)]− under the same conditions. Potentiometric titrations have determined the thermodynamic formation constant of the [In(octapa)]− complex to be log KML = 26.8(1). Through the same set of analyses, the [111/115In(decapa)]2– complex was found to have nonoptimal stability, with H5decapa (N5O5) being more suitable for larger metal ions due to its higher potential denticity (e.g., lanthanides and actinides). Our initial investigations have revealed the acyclic chelator H4octapa to be a valuable alternative to the macrocycle DOTA for use with 111In, and a significant improvement to the acyclic chelator DTPA.This publication has 56 references indexed in Scilit:
- Modular Strategy for the Construction of Radiometalated Antibodies for Positron Emission Tomography Based on Inverse Electron Demand Diels–Alder Click ChemistryBioconjugate Chemistry, 2011
- Generator-based PET radiopharmaceuticals for molecular imaging of tumours: on the way to THERANOSTICSDalton Transactions, 2011
- A practical guide to the construction of radiometallated bioconjugates for positron emission tomographyDalton Transactions, 2011
- Radioimmunotherapy with 90Y-ibritumomab tiuxetan is a safe and efficient treatment for patients with B-cell lymphoma relapsed after auto-SCT: an analysis of the international RIT-NetworkBone Marrow Transplantation, 2010
- Unconventional Nuclides for RadiopharmaceuticalsMolecular Imaging, 2010
- Radioimmunotherapy of non-Hodgkin’s lymphoma: a critical appraisalExpert Review of Clinical Immunology, 2005
- Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC.European Journal of Nuclear Medicine and Molecular Imaging, 1999
- Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imagingQJM: An International Journal of Medicine, 1998
- Capromab PendetideDrugs & Aging, 1998
- Production of positron-emitting 110mIn via the processApplied Radiation and Isotopes, 1997